PCM
IMRX icon

Prelude Capital Management’s Immuneering IMRX Stock Holding History

Prelude Capital Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$154K Sell
29,219
-50,781
-63% -$260K 0.01% 971
2025
Q4 		$526K Buy
80,000
+7,533
+10% +$48.4K 0.04% 510
2025
Q3 		$507K Buy
+72,467
New +$376K 0.04% 503

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's IMRX Position: Q1 2026 in Review

Prelude Capital Management reduced its Immuneering (IMRX) stake by 63% in Q1 2026, selling an estimated $260K and leaving 29,219 shares worth $154K. The position accounts for 0.01% of the portfolio, ranked #971.

Prelude Capital Management first reported a position in IMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $526K in Q4 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Prelude Capital Management held 29,219 shares of Immuneering worth $154K as of Q1 2026.
  • Prelude Capital Management sold 50,781 Immuneering shares in Q1 2026, an estimated $260K.
  • Immuneering made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #971 holding.
  • Prelude Capital Management first reported a position in Immuneering in Q3 2025 and has held it in 3 quarters since.
  • Prelude Capital Management's Immuneering position peaked at $526K in Q4 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.